Navigation Links
BioRealm to Develop Universal Genetic Screening Tool for Tobacco Addiction and Treatment

Los Angeles, CA (PRWEB) June 20, 2012

BioRealm, LLC announced today that it has been awarded a Small Business Innovative Research contract by the U.S. National Institute on Drug Abuse (NIDA) to develop a universal genetic screening tool for tobacco addiction and treatment approaches. BioRealm’s “Smokescreen” product will integrate recent advances in tobacco addiction research and allow researchers to study thousands of an individual’s genetic variants related to tobacco dependence and treatment response.

According to the Centers for Disease Control and Prevention (CDC), smoking is the leading cause of preventable disease in the U.S., resulting in $96 billion in annual health care costs. Despite the availability of numerous smoking cessation products and treatments, effectiveness varies greatly and people often relapse. Studies have shown that genetic variation plays a significant role in nicotine dependence, including the ability to quit smoking and response to nicotine replacement therapy and medication. However, the genetics of tobacco addiction are not yet fully understood.

Addiction researchers have so far been limited by the small number of participants in clinical trials, and the lack of a validated genetic screening tool and centralized database for storing results. “The Smokescreen aims to solve these problems by featuring a uniform set of genetic variants, with genotyping results automatically stored and accessible via a secure cloud-based application”, stated Christopher Edlund, Bioinformatics Principal at BioRealm. “The ability to seamlessly share and compare data across multiple studies will enable researchers and clinicians to more effectively investigate tobacco addiction”.

Scientists at BioRealm envision the Smokescreen to be the standard genetic test used by clinical trials for smoking cessation. “The Smokescreen will be an invaluable resource for developing personalized smoking cessation treatments and ultimately reducing tobacco use in the U.S.”, said BioRealm co-founder Dr. James Baurley.

Additional information related to the Smokescreen product can be found at

About BioRealm

Founded in 2006, BioRealm develops solutions for genetic research and the biomedical industry.

Source: BioRealm, LLC

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. NASA develops super-black material that absorbs light across multiple wavelength bands
2. Gated STED -- developing the next generation of super-resolution microscopes
3. Fitzsimons Redevelopment Authority Rolls Out First Phase of Strategic Refocus With Appointment of Four Key Leaders in The Bioscience Industry to Its Board of Directors
4. Multidisciplinary team of researchers develop world’s lightest material
5. UCLA team develops highly efficient method for creating flexible, transparent electrodes
6. Roche NimbleGen and BGI Develop Advanced MHC Region Capture Technology for Human Disease and Biomedical Research
7. Quanterix Receives Funding From the Department of Homeland Security to Develop Test for Botulinum Toxin
8. AtheroNova and Maxwell Biotech Group Ratify Agreement to Develop New Atherosclerosis Drug
9. Immune Design Corp. Appoints Wayne R. Gombotz, Ph.D. as Chief Development Officer
10. OvaGene Oncology Collaborates With Moffitt Cancer Center to Develop and Commercialize microRNAs Associated With Chemotherapeutic Drug Response
11. Researchers develop one of the worlds smallest electronic circuits
Post Your Comments:
(Date:10/13/2015)... October 13, 2015      Q ... company, has entered into a strategic relationship with Wombat ... and Paris, France based strategic ... --> This collaborative arrangement gives Q BioMed ... advisory team as well as long established pharmaceutical industry ...
(Date:10/13/2015)... (PRWEB) , ... October 13, 2015 , ... Clinovo recently ... expertise to the company’s fast growing clinical data solutions business. , Jeff Parr has ... companies of all sizes, including Avery Dennison, Thermo Fisher, and Ab Sciex to name ...
(Date:10/12/2015)... BRUSSELS , Oct. 12, 2015  Amgen (NASDAQ: ... additional findings from an exploratory sub-study of the previously reported ... today in an oral plenary session at the American Society ... Seattle . 2 ... small exploratory sub-study data showed that, at month 12, the ...
(Date:10/12/2015)... October 12, 2015 cell surface marker ... by 2022, according to a new report by Grand View ... rise in incidence of oncology diseases and other cell-associated disorders. ... expected to reach USD 6.49 billion by 2022, according to ... in demand can be attributed to rise in incidence of ...
Breaking Biology Technology:
(Date:10/8/2015)... LAKE CITY , 8. Oktober 2015 ... TRCK), ein global tätiges Unternehmen des Bereiches ... einem Vertrag mit der Gefängnisbehörde Virginias (Department ... dessen Rahmen elektronische Überwachungsdienste für alle Strafen ... Derek Cassell , Präsident für den ...
(Date:10/7/2015)... GOTHENBURG, Sweden , October 8, 2015 ... estimates the revenues for Fingerprint Cards (FPC) during third quarter ... communicated revenue guidance of around 860 MSEK that was communicated ... Considering a further strengthened delivery capacity and a continued ... fourth quarter 2015 is estimated to be higher than during ...
(Date:10/6/2015)... SALT LAKE CITY , Oct. 6, 2015 /PRNewswire/ ... solutions company, announced today that it has signed a ... electronic monitoring services across the full range of sentences ... Track Group,s President of the Americas. "This contract with ... Eastern region of the US and advances our position ...
Breaking Biology News(10 mins):